Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
Calland, Noemie
Sahuc, Marie-Emmanuelle
Belouzard, Sandrine
Pene, Veronique
Bonnafous, Pierre
Mesalam, Ahmed Atef
Deloison, Gaspard
Descamps, Veronique
Sahpaz, Sevser
Wychowski, Czeslaw
Lambert, Olivier
Brodin, Priscille
Duverlie, Gilles
Meuleman, Philip
Rosenberg, Arielle R.
Dubuisson, Jean
Rouille, Yves
Seron, Karin
Journal of Virology, 2015
Sandrine Belouzard
Belouzard Sandrine
ORCID: 0000-0002-9972-4054
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Utilization of human DC-SIGN and L-SIGN for entry and infection of host cells by the New World arenavirus, Junin virus
10.1016/j.bbrc.2013.10.106
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein
10.3390/v4061011
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Elastase-mediated Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein at Discrete Sites within the S2 Domain
10.1074/jbc.M110.103275
Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
10.1073/pnas.0809524106
Characterization of a Highly Conserved Domain within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain with Characteristics of a Viral Fusion Peptide
10.1128/JVI.00079-09
SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion
10.1016/j.virol.2009.07.038
Molecular architecture of the bipartite fusion loops of vesicular stomatitis virus glycoprotein G, a class III viral fusion protein
10.1074/jbc.M708955200
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway.
10.1074/jbc.m400508200
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions.
10.1074/jbc.m406315200
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis.
10.1128/jvi.79.16.10826-10829.2005
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis.
10.1038/sj.emboj.7600989
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus.
10.1128/jvi.80.6.2832-2841.2006
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/JVI.00478-17
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll-Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.RA119.008964
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress.
10.3390/cells10082047
Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
10.1128/aac.00097-21
Olivier Lambert
Lambert Olivier
ORCID: 0000-0002-5651-8082
Trimeric structure of OprN and OprM efflux proteins from Pseudomonas aeruginosa, by 2D electron crystallography
10.1016/j.jsb.2005.01.001
High-yield preparation of polystyrene/silica clusters of controlled morphology
10.1039/c2py20058a
Polyphenols inhibit hepatitis C virus entry by a new mechanism of action
10.1128/JVI.01473-15
Minimal nanodisc without exogenous lipids for stabilizing membrane proteins in detergent-free buffer
10.1016/j.bbamem.2019.01.013
Modeling leakage kinetics from multilamellar vesicles for membrane permeability determination: Application to glucose
10.1529/biophysj.106.088401
Hepatitis B subvirus particles display both a fluid bilayer membrane and a strong resistance to freeze drying: A study by solid-state NMR, light scattering, and cryo-electron microscopy/tomography
10.1096/fj.13-232843
An approach to the intramolecular localization of the thiol ester bonds in the internal cavity of human α2 -macroglobulin based on correspondence analysis
10.1006/jsbi.1994.1016
Multilamellar liposomes entrapping aminosilane-modified maghemite nanoparticles: “Magnetonions”
10.1039/c0cp00231c
Two-dimensional crystallization on lipid layer: A successful approach for membrane proteins
10.1006/jsbi.1999.4155
The encapsulation of DNA molecules within biomimetic lipid nanocapsules
10.1016/j.biomaterials.2009.03.009
Three-dimensional reconstruction of Limulus polyphemus hemocyanin from cryoelectron microscopy
10.1006/jmbi.1996.0840
Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference
10.1073/pnas.0707431104
Metallic oxide nanoparticle translocation across the human bronchial epithelial barrier
10.1039/c4nr07079h
Protein-mediated DNA transfer into liposomes
10.1046/j.1365-2958.1998.01107.x
Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer.
10.1093/nar/gnh153
Membrane protein selectively oriented on solid support and reconstituted into a lipid membrane
10.1021/la062227z
Self-assembling complexes between binary mixtures of lipids with different linkers and nucleic acids promote universal mRNA, DNA and siRNA delivery
10.1016/j.jconrel.2017.01.041
Galactosylated multimodular lipoplexes for specific gene transfer into primary hepatocytes
10.1002/jgm.1212
Synthesis and self-assembly of branched glycopolypeptides: Effect of topology and conformation
10.1039/c3fd00082f
Regioselective Coating of Tetrapod-like Clusters with Silica
10.1080/15421406.2014.967651
Organization of reconstituted lipoprotein MexA onto supported lipid membrane
10.1007/s00249-007-0208-5
Morphological characterization and fusion properties of triglyceride-rich lipoproteins obtained from cells transduced with hepatitis c virus glycoproteins
10.1074/jbc.M110.131664
Characterization of hepatitis C virus pseudoparticles by cryo-transmission electron microscopy using functionalized magnetic nanobeads
10.1099/vir.0.021071-0
The homeodomain derived peptide penetratin induces curvature of fluid membrane domains
10.1371/journal.pone.0001938
Three-dimensional reconstruction from a frozen-hydrated specimen of the chiton Lepidochiton sp. hemocyanin
10.1006/jmbi.1994.1757
N-Heterocyclic Carbene-Polyethylenimine Platinum Complexes with Potent in Vitro and in Vivo Antitumor Efficacy
10.1021/acs.bioconjchem.6b00320
The motor protein Myosin-X transports VE-cadherin along filopodia to allow the formation of early endothelial cell-cell contacts
10.1128/MCB.01226-09
Detergent removal by non-polar polystyrene beads: Applications to membrane protein reconstitution and two-dimensional crystallization
10.1007/s002490050138
Caveolae-mediated effects of TNF-α on human skeletal muscle cells
10.1016/j.yexcr.2018.07.027
Quaternary structure of Octopus vulgaris hemocyanin: Three-dimensional reconstruction from frozen-hydrated specimens andintramolecular location of functional units Ov e and Ov b
10.1006/jmbi.1994.1269
Cryo-electron tomography of nanoparticle transmigration into liposome
10.1016/j.jsb.2009.07.006
Novel Organization and Properties of Annexin 2-Membrane Complexes
10.1074/jbc.M313657200
Paromomycin and neomycin B derived cationic lipids: Synthesis and transfection studies
10.1016/j.jconrel.2011.12.019
DNA delivery by phage as a strategy for encapsulating toroidal condensates of arbitrary size into liposomes
10.1073/pnas.130187297
Use of octyl β-thioglucopyranoside in two-dimensional crystallization of membrane proteins
10.1006/jsbi.2001.4344
Three-Dimensional Reconstruction of the Hemocyanin of the Protobranch Bivalve Mollusk Nucula hanleyi from Frozen-Hydrated Specimens
10.1006/abbi.1995.1287
Design of Ionizable Lipids to Overcome the Limiting Step of Endosomal Escape: Application in the Intracellular Delivery of mRNA, DNA, and siRNA
10.1021/acs.jmedchem.5b01679
Structure of reconstituted bacterial membrane efflux pump by cryo-electron tomography
10.1016/j.bbamem.2010.06.019
Oxidative stress induces Caveolin 1 degradation and impairs Caveolae functions in skeletal muscle cells
10.1371/journal.pone.0122654
Synthesis of stable, gold-particle-containing onion-type multilamellar vesicles. Influence of particle size on the onions' internal structure
10.1088/0957-4484/17/5/005
Two-dimensional structures of the shiga toxin B-subunit and of a chimera bound to the glycolipid receptor Gb3
10.1016/S1047-8477(02)00504-X
Structure determination of membrane protein by both cryo-electron tomography and single particle analysis.
10.1007/978-1-60761-762-4_11
A chemical synthetic route towards "Colloidal molecules"
10.1002/anie.200802562
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Nitroxide-Mediated Polymerization-Induced Self-Assembly of Block Copolymers at the Surface of Silica Particles: Toward New Hybrid Morphologies
10.1021/acs.macromol.7b00033
Treatment of influenza virus with Beta-propiolactone alters viral membrane fusion
10.1016/j.bbamem.2013.09.021
Probing the in vitro mechanism of action of cationic lipid/DNA lipoplexes at a nanometric scale
10.1093/nar/gkq921
Amphiphilic block copolymers enhance the cellular uptake of DNA molecules through a facilitated plasma membrane transport
10.1093/nar/gkq922
Use of detergents in two-dimensional crystallization of membrane proteins
10.1016/S0005-2736(00)00307-2
Involvement of caveolin-1 and CD36 in native LDL endocytosis by endothelial cells
10.1016/j.bbagen.2019.01.005
FhuA-mediated phage genome transfer into liposomes: A cryo-electron tomography study
10.1016/S0960-9822(01)00349-9
Electrokinetic assembly of one-dimensional nanoparticle chains with cucurbit[7]uril controlled subnanometer junctions
10.1021/nl403224q
Asymmetrical membranes and surface tension
10.1016/S0006-3495(02)73915-5
An 8-Å projected structure of FhuA, a 'ligand-gated' channel of the Escherichia coli outer membrane
10.1006/jsbi.1999.4115
Magnetic multilamellar liposomes produced by in situ synthesis of iron oxide nanoparticles: "Magnetonions"
10.1021/jp901105c
Planar submicronic silica-polystyrene particles obtained by substrate-directed shaping
10.1039/b901901d
Liposome-based Formulation for Intracellular Delivery of Functional Proteins
10.1038/mtna.2015.17
Interaction of Aβ1-42 Amyloids with Lipids Promotes "Off-Pathway" Oligomerization and Membrane Damage
10.1021/bm501837w
A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles
10.1089/104303402760293592
FhuA, an Escherichia coli outer membrane protein with a dual function of transporter and channel which mediates the transport of phage DNA
10.1016/S0300-9084(00)80004-8
Piceatannol and other wine stilbenes: A pool of inhibitors against α-synuclein aggregation and cytotoxicity
10.3390/nu8060367
Antibiotic export by MexB multidrug efflux transporter is allosterically controlled by a MexA-OprM chaperone-like complex
10.1038/s41467-020-18770-5
Relationships between the physicochemical properties of an amphiphilic triblock copolymers/DNA complexes and their intramuscular transfection efficiency
10.1093/nar/gkl860
Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses
10.1016/j.vaccine.2019.05.012
Structural organization of molluscan hemocyanins
10.1016/0248-4900(96)89453-6
A yeast toxic mutant of HET-s amyloid disrupts membrane integrity
10.1016/j.bbamem.2012.04.013
Tripartite assembly of RND multidrug efflux pumps
10.1038/ncomms10731
Phage DNA transfer into liposomes
10.1016/S0076-6879(03)73029-8
A new 'gel-like' phase in dodecyl maltoside-lipid mixtures: Implications in solubilization and reconstitution studies
10.1016/S0006-3495(98)74015-9
Synthesis of unsymmetrical saturated or diacetylenic cationic bolaamphiphiles
10.1016/j.tetlet.2008.10.073
Spheres growing on a sphere: A model to predict the morphology yields of colloidal molecules obtained through a heterogeneous nucleation route
10.1021/la301857h
Physicochemical parameters of non-viral vectors that govern transfection efficiency
10.2174/156652308786070961
Further Approaches to the Quaternary Structure of Octopus Hemocyanin: A Model Based on Immunoelectron Microscopy and Image Processing
10.1006/abbi.1993.1388
The basic framework of VE-cadherin junctions revealed by cryo-EM
10.1016/j.jmb.2004.12.053
Shaping quaternary assemblies of water-soluble non-peptide helical foldamers by sequence manipulation
10.1038/nchem.2353
Quaternary ammonium groups exposed at the surface of silica nanoparticles suitable for DNA complexation in the presence of cationic lipids
10.1021/acs.jpcb.5b01834
Different molecular arrangements of the tetrameric annexin 2 modulate the size and dynamics of membrane aggregation
10.1016/j.bbamem.2010.05.001
Three-dimensional reconstruction of the chlorocruorin of the polychaete annelid Eudistylia vancouverii
10.1006/jmbi.1996.0012
How the stereochemistry of a central cyclopentyl ring influences the self-assembling properties of archaeal lipid analogues: Synthesis and cryoTEM observations
10.1021/jo201827h
The formation of supported lipid bilayers on silica nanoparticles revealed by cryoelectron microscopy
10.1021/nl048153y
Lipid domain separation, bilayer thickening and pearling induced by the cell penetrating peptide penetratin
10.1016/j.bbamem.2009.12.024
Visualization of adherent cell monolayers by cryo-electron microscopy: A snapshot of endothelial adherens junctions
10.1016/j.jsb.2015.10.009
Internalization and fate of silica nanoparticles in C2C12 skeletal muscle cells: Evidence of a beneficial effect on myoblast fusion
10.2147/IJN.S74158
Cancer-specific transgene expression mediated by systemic injection of nanoparticles
10.1158/0008-5472.CAN-08-2657
Three-dimensional reconstruction of the αD and βC -hemocyanins of Helix pomatia from frozen-hydrated specimens
10.1016/s0022-2836(95)80061-1
Three-dimensional reconstruction of Macrobdella decora (leech) hemoglobin by cryoelectron microscopy
10.1016/S0006-3495(96)79762-X
Colloidal alchemy: Conversion of polystyrene nanoclusters into gold
10.1002/cnma.201600315
Important role of phosphoramido linkage in imidazole-based dioleyl helper lipids for liposome stability and primary cell transfection
10.1002/jgm.2869
Structure of artificial and natural VE-cadherin-based adherens junctions
10.1042/BST0360189
Three-dimensional reconstruction of Sepia officinalis hemocyanin from frozen-hydrated specimens
10.1006/abbi.1995.1126
Sterically stabilized BGTC-based lipoplexes: Structural features and gene transfection into the mouse airways in vivo
10.1002/jgm.211
Gold fractal structures spontaneously grown in sheared lamellar phase
10.1039/b605988k
Multipod-like silica/polystyrene clusters
10.1039/c5nr07613g
Single lipoaminoglycoside promotes efficient intracellular antibody delivery: A comprehensive insight into the mechanism of action
10.1016/j.nano.2017.09.005
Annexin-A6 presents two modes of association with phospholipid membranes. A combined QCM-D, AFM and cryo-TEM study
10.1016/j.jsb.2009.03.007
Two-dimensional crystallization of proteins on lipid monolayers at the air - Water interface and transfer to an electron microscopy grid
10.1016/S0022-0248(98)00834-3
Charge detection mass spectrometry for the characterization of mass and surface area of composite nanoparticles
10.1021/jp510081v
Production of magnetic multilamellar liposomes as highly T2-efficient MRI contrast agents
10.1016/j.nano.2010.10.011
Structural analysis of junctions formed between lipid membranes and several annexins by cryo-electron microscopy
10.1006/jmbi.1997.1183
New insights into the nucleation and growth of PS nodules on silica nanoparticles by 3D cryo-electron tomography
10.1039/b710137f
Coiled-coil oligomerization controls localization of the plasma membrane REMORINs
10.1016/j.jsb.2018.02.003
Structural characterization of the EmrAB-TolC efflux complex from E. coli
10.1016/j.bbamem.2020.183488
A Cell-Penetrating Foldamer with a Bioreducible Linkage for Intracellular Delivery of DNA
10.1002/anie.201504884
Gene transfer by histidylated lipopolyplexes: A dehydration method allowing preservation of their physicochemical parameters and transfection efficiency
10.1016/j.ijpharm.2011.04.009
Reconstitution of membrane proteins into nanodiscs for single-particle electron microscopy
10.1007/978-1-4939-7151-0_17
Lipidic Aminoglycoside Derivatives: A New Class of Immunomodulators Inducing a Potent Innate Immune Stimulation
10.1002/advs.201900288
Structure of membrane-bound annexin A5 trimers: A hybrid Cryo-EM - X-ray crystallography study
10.1006/jmbi.2000.4183
Yves Rouillé
Rouillé Yves
ORCID: 0000-0003-0788-9271
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon
10.1016/s0014-5793(97)00892-2
Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1
10.1074/jbc.272.52.32810
Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: A potential mechanism for its inactivation
10.1073/pnas.93.10.4919
DISTINCT HYDRO-OSMOTIC RECEPTORS FOR THE NEUROHYPOPHYSEAL PEPTIDES VASOTOCIN AND HYDRINS IN THE FROG RANA-ESCULENTA
10.1016/0143-4179(95)90039-x
HYPERPROINSULINAEMIA IN OBESE FAT/FAT MICE ASSOCIATED WITH A CARBOXYPEPTIDASE-E MUTATION WHICH REDUCES ENZYME-ACTIVITY
10.1038/ng0695-135
PROTEOLYTIC PROCESSING MECHANISMS IN THE BIOSYNTHESIS OF NEUROENDOCRINE PEPTIDES - THE SUBTILISIN-LIKE PROPROTEIN CONVERTASES
10.1006/frne.1995.1012
ACTION OF NEUROHYPOPHYSEAL GRANULE LYS-ARG ENDOPEPTIDASE ON SYNTHETIC POLYPEPTIDES COMPRISING THE PROCESSING SEQUENCE OF PROVASOPRESSIN-NEUROPHYSIN
10.1007/bf01200246
PROGLUCAGON IS PROCESSED TO GLUCAGON BY PROHORMONE CONVERTASE PC2 IN ALPHA-TC1-6 CELLS
10.1073/pnas.91.8.3242
SPECIAL EVOLUTION OF NEUROHYPOPHYSEAL HORMONES IN CARTILAGINOUS FISHES - ASVATOCIN AND PHASVATOCIN, 2 OXYTOCIN-LIKE PEPTIDES ISOLATED FROM THE SPOTTED DOGFISH (SCYLIORHINUS-CANICULUS)
10.1073/pnas.91.23.11266
A NEUROSECRETORY GRANULE LYS-ARG CA2+-DEPENDENT ENDOPEPTIDASE PUTATIVELY INVOLVED IN PROOXYTOCIN AND PROVASOPRESSIN PROCESSING
10.1016/0143-4179(92)90050-7
EVIDENCE FOR DISTINCT DIBASIC PROCESSING ENDOPEPTIDASES WITH LYS-ARG AND ARG-ARG SPECIFICITIES IN NEUROHYPOPHYSEAL SECRETORY GRANULES
10.1016/0006-291x(92)91618-z
PROCESSING ENDOPEPTIDASE DEFICIENCY IN NEUROHYPOPHYSEAL SECRETORY GRANULES OF THE DIABETES-INSIPIDUS (BRATTLEBORO) RAT
10.1007/bf01122032
HETEROLOGUE CONVERSION OF AMPHIBIAN HYDRIN-2 INTO VASOTOCIN THROUGH BOVINE GRANULE ALPHA-AMIDATING ENZYME
10.1111/j.1365-2826.1991.tb00233.x
NEUROHYPOPHYSEAL HORMONES AS MOLECULAR EVOLUTIONARY TRACERS - INVESTIGATIONS ON THE STURGEONS ACIPENSER-STELLATUS AND ACIPENSER-GULDENSTADTI
10.1016/0305-0491(91)90280-q
EVOLUTIONARY SPECIFICITY OF HYDRINS, NEW HYDROOSMOTIC NEUROPEPTIDES - OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY) IN THE TOAD BUFO-MARINUS BUT NOT IN THE VIPER VIPERA-ASPIS
10.1016/0014-5793(90)80783-f
IDENTIFICATION OF 2 TYPES OF NEUROPHYSINS IN XENOPUS-LAEVIS NEUROINTERMEDIATE PITUITARY HOMOLOGOUS TO MAMMALIAN MSEL-NEUROPHYSIN AND VLDV-NEUROPHYSIN
10.1016/0143-4179(90)90142-l
OCCURRENCE OF HYDRIN-2 (VASOTOCINYL-GLY), A NEW HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDE, IN SECRETORY GRANULES ISOLATED FROM THE FROG (RANA-ESCULENTA) NEUROINTERMEDIATE PITUITARY
10.1159/000125343
HYDRINS, HYDROOSMOTIC NEUROHYPOPHYSEAL PEPTIDES - OSMOREGULATORY ADAPTATION IN AMPHIBIANS THROUGH VASOTOCIN PRECURSOR PROCESSING
10.1073/pnas.86.14.5272
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOTOCIN, MESOTOCIN, MSEL-NEUROPHYSINS AND VLDV-NEUROPHYSINS FROM GOOSE NEUROHYPOPHYSIS
10.1016/0143-4179(89)90090-5
PARTICULAR PROCESSING OF PRO-OPIOMELANOCORTIN IN XENOPUS-LAEVIS INTERMEDIATE PITUITARY - SEQUENCING OF ALPHA-MELANOCYTE-STIMULATING, AND BETA-MELANOCYTE-STIMULATING HORMONES
10.1016/0014-5793(89)80224-8
DUAL DUPLICATION OF NEUROHYPOPHYSEAL HORMONES IN AN AUSTRALIAN MARSUPIAL - MESOTOCIN, OXYTOCIN, LYSINE VASOPRESSIN AND ARGININE VASOPRESSIN IN A SINGLE GLAND OF THE NORTHERN BANDICOOT (ISOODON-MACROURUS)
10.1016/0006-291x(88)90691-2
ISOLATION OF NEUROSECRETORY GRANULES CONTAINING VASOPRESSIN AND MSEL-NEUROPHYSIN FROM GUINEA-PIG NEUROINTERMEDIATE PITUITARY
10.1016/0143-4179(88)90025-x
NEUROHYPOPHYSEAL HORMONES OF THE 1-MONTH-OLD BOVINE FETUS - ABSENCE OF VASOTOCIN DURING MAMMAL DEVELOPMENT
10.1016/0014-5793(88)80113-3
THE DISTRIBUTION OF LYSINE VASOPRESSIN (LYSIPRESSIN) IN PLACENTAL MAMMALS - A REINVESTIGATION OF THE HIPPOPOTAMIDAE (HIPPOPOTAMUS-AMPHIBIUS) AND TAYASSUIDAE (TAYASSU-ANGULATUS) FAMILIES
10.1016/0016-6480(88)90277-8
EVOLUTION OF MARSUPIALS TRACED BY THEIR NEUROHYPOPHYSEAL HORMONES - MICROIDENTIFICATION OF MESOTOCIN AND ARGININE VASOPRESSIN IN 2 AUSTRALIAN FAMILIES, DASYURIDAE AND PHASCOLARCTIDAE
10.1016/0016-6480(87)90195-x
GUINEA-PIG NEUROHYPOPHYSEAL HORMONES - PECULIAR PROCESSING OF THE 3-DOMAIN VASOPRESSIN PRECURSOR
10.1016/0014-5793(87)81294-2
Hexim1, a Novel Regulator of Leptin Function, Modulates Obesity and Glucose Disposal
10.1210/me.2015-1211
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus
10.1128/jvi.00404-16
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Recent advances in human viruses imaging studies
10.1002/jobm.201500575
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/jvi.00192-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
FTO contributes to hepatic metabolism regulation through regulation of leptin action and STAT3 signalling in liver
10.1186/1478-811x-12-4
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
HCV replication and assembly: a play in one act
10.2217/fvl.11.69
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/jvi.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/jvi.01190-09
LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice
10.1172/jci34997
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/jvi.00024-06
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/jvi.80.6.2832-2841.2006
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis
10.1038/sj.emboj.7600989
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/jvi.79.16.10826-10829.2005
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/s0074-7696(05)45006-8
Significance of prohormone convertase 2, PC2, mediated initial cleavage at the proglucagon interdomain site, Lys70-Arg71, to generate glucagon
10.1210/en.2004-1118
Low levels of expression of leptin receptor at the cell surface result from constitutive endocytosis and intracellular retention in the biosynthetic pathway
10.1074/jbc.M400508200
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/jvi.78.22.12591-12602.2004
Visualization of TGN to endosome trafficking through fluorescently labeled MPR and AP-1 in living cells
10.1091/mbc.E02-06-0338
Dynamic processing of neuropeptides - Sequential conformation shaping of neurohypophysial preprohormones during intraneuronal secretory transport
10.1385/jmn:18:3:223
Yeast Vps55p, a functional homolog of human obesity receptor gene-related protein, is involved in late endosome to vacuole trafficking
10.1091/mbc.01-12-0597
Targeting of lysosomal proteins
10.1006/scdb.2000.0168
Unique evolution of neurohypophysial hormones in cartilaginous fishes: Possible implications for urea-based osmoregulation
10.1002/(sici)1097-010x(19991001)284:5<475::aid-jez2>3.0.co;2-9
Adaptive evolution of water homeostasis regulation in amphibians: Vasotocin and hydrins
10.1016/s0248-4900(97)83380-1
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
10.1073/pnas.94.13.6646
Molecular evolution of neurohypophysial hormones in relation to osmoregulation: the two fish options
10.1023/a:1007720909113
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Endospanin1 affects oppositely body weight regulation and glucose homeostasis by differentially regulating central leptin signaling.
10.1016/j.molmet.2016.10.009
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly.
10.1128/jvi.00048-17
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics.
10.1016/j.jviromet.2017.04.009
Hepatitis C virus life cycle and lipid metabolism.
10.3390/biology3040892
Endospanin-2 enhances skeletal muscle energy metabolism and running endurance capacity
10.1172/jci.insight.98081
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence
10.3390/v11020165
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and seasonal coronaviruses
10.1101/2021.05.19.444823
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal.
10.1074/jbc.ra119.008964
Ultrastructural modifications induced by SARS-CoV-2 in Vero cells: a kinetic analysis of viral factory formation, viral particle morphogenesis and virion release.
10.1007/s00018-020-03745-y
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
Karin Seron
Seron Karin
ORCID: 0000-0002-9667-133X
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/jvi.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/jvi.01402-14
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
Structure-activity studies of (-)-epigallocatechin gallate derivatives as HCV entry inhibitors
10.1016/j.bmcl.2014.07.051
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
Endospanins Regulate a Postinternalization Step of the Leptin Receptor Endocytic Pathway
10.1074/jbc.M111.224857
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity
10.1073/pnas.0706671104
ACDC/adiponectin polymorphisms are associated with severe childhood and adult obesity
10.2337/diabetes.55.02.06.db05-0971
Distinct impaired regulation of SOCS3 and long and short isoforms of the leptin receptor in visceral and subcutaneous fat of lean and obese women
10.1016/j.bbrc.2006.07.068
Genetic study of the CD36 gene In a French diabetic population
10.1016/s1262-3636(07)70143-x
GAD2 on chromosome 10p12 is a candidate gene for human obesity
10.1371/journal.pbio.0000068
Molecular cloning, functional complementation in Saccharomyces cerevisiae and enzymatic properties of phosphatidylinositol synthase from the protozoan parasite Toxoplasma gondii
10.1046/j.1432-1327.2000.01749.x
Disruption of six novel genes from the left arm of chromosome XV of Saccharomyces cerevisiae and basic phenotypic analysis of the generated mutants
10.1002/(sici)1097-0061(19990115)15:1<73::aid-yea341>3.0.co;2-q
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase
10.1016/s0166-0934(96)02166-0
Efficient transcription obtained by a new procedure of the tRNA-like structure of turnip yellow mosaic virus by a template-dependent and specific viral RNA polymerase (vol 64, pg 181, 1997)
10.1016/s0166-0934(96)02249-5
Expression of the 69K movement protein of turnip yellow mosaic virus in insect cells
10.1006/viro.1996.0246
Gene expression from viral RNA genomes
10.1007/bf00039391
Vascular movement of plant viruses
10.1094/mpmi-9-0435
IN-VITRO TRANSCRIPTS OF TURNIP YELLOW MOSAIC-VIRUS ENCOMPASSING A LONG 3' EXTENSION OR PRODUCED FROM A FULL-LENGTH CDNA CLONE HARBORING A 2 KB-LONG PCR-AMPLIFIED SEGMENT ARE INFECTIOUS
10.1016/s0923-2516(06)80049-x
Entry and release of hepatitis C virus in polarized human hepatocytes.
10.1128/jvi.00478-17
An ecological approach to discover new bioactive extracts and products: the case of extremophile plants.
10.1111/jphp.12728
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin.
10.1016/j.antiviral.2016.07.011
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus
10.1101/325126
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource.
10.1016/j.jep.2020.112735
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus.
10.1021/acsami.9b15032
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication.
10.1128/jvi.02009-18
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Correction for Belouzard et al., "Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes".
10.1128/jvi.00309-18
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
A yeast t-SNARE involved in endocytosis.
10.1091/mbc.9.10.2873
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone
10.3390/toxins9070227
10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections
10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis
10.1016/j.drudis.2017.05.005
10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria
10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis
10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis
10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420
10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters
10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro
10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization
10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin
10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection
10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1
10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo
10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges
10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system
10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro
10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays
10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches
10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways
10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro
10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings
10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis
10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence
10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis
10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors
10.1021/jm200076a
High-content screening in infectious diseases
10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ
10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery
10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting
10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure
10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors
10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems
10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP
10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans
10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity
10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis
10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva
10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images
10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues
10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis
10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents
10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence
10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection
10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence
10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis
10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity
10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics
10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions
10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine
10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6
10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens
10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex
10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis
10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex
10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides
10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti
10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro
10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase
10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides
10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase
10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides
10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions
10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus
10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton
10.15252/embr.201744371
10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles
10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays
10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids
10.1073/pnas.1707840114
10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors
10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis
10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation
10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis
10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis
10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs
10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis
10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages
10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling
10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection
10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening
10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections
10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation
10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters
10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis
10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells
10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria
10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation
10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls
10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies.
10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity.
10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds.
10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis.
10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Worms' Antimicrobial Peptides.
10.3390/md17090512
T(oo)bAd.
10.1038/s41589-019-0347-x
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture.
10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Cell microbiology interview
10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts
10.1099/mgen.0.000505
Philip Meuleman
Meuleman Philip
ORCID: 0000-0001-6821-234X
Blocking HCV entry as potential antiviral therapy
10.2217/fvl.12.47
HCV animal models and liver disease
10.1016/j.jhep.2014.07.013
Human but Not Mouse Hepatocytes Respond to Interferon-Lambda In Vivo
10.1371/journal.pone.0087906
Hepatitis C virus infection and related liver disease: the quest for the best animal model
10.3389/fmicb.2013.00212
The emergence of hepatitis E virus in Europe
10.2217/fvl.15.29
Murine IL-2 receptor beta chain blockade improves human leukocyte engraftment in SCID mice
10.1002/(sici)1521-4141(199810)28:10<3221::aid-immu3221>3.0.co;2-s
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection
10.1172/jci70349
Molecular detection and quantification of Plasmodium falciparum-infected human hepatocytes in chimeric immune-deficient mice
10.1186/1475-2875-12-430
Human Skin-Derived Precursor Cells Are Poorly Immunogenic and Modulate the Allogeneic Immune Response
10.1002/stem.1692
Metabolism of methylstenbolone studied with human liver microsomes and the uPA +/+ -SCID chimeric mouse model
10.1002/bmc.3105
Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1
10.1074/jbc.m114.617787
Is hepatitis E virus an emerging problem in industrialized countries?
10.1002/hep.27990
Animal models for the study of HCV
10.1016/j.coviro.2015.04.009
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/jvi.01473-15
Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody
10.1038/nbt.3179
Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1
10.1002/hep.28111
Anti-CD81 but not anti-SR-BI blocks Plasmodium falciparum liver infection in a humanized mouse model
10.1093/jac/dkv019
G09 : Targeting a host-cell entry factor barricades antiviral resistant HCV variants from on-therapy breakthrough in human-liver mice
10.1016/s0168-8278(15)30058-1
P0674 : Clinically approved T-type calcium channel inhibitors prevent hepatitis C virus (HCV) membrane fusion in a genotype-dependent manner
10.1016/s0168-8278(15)30878-3
P0676 : Clearance of persistent hepatitis c virus infection using a monoclonal antibody specific for tight junction protein claudin-1
10.1016/s0168-8278(15)30880-1
In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200
10.1002/rcm.6673
In vitro and in vivo metabolisms of 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)
10.1007/s11419-013-0179-4
Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum
10.1186/1475-2875-13-136
Artemisinin Analogues as Potent Inhibitors of In Vitro Hepatitis C Virus Replication
10.1371/journal.pone.0081783
A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites
10.7554/elife.03582
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
10.1002/hep.27196
Cell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted Variant
10.1128/jvi.01362-07
Immune Suppression Uncovers Endogenous Cytopathic Effects of the Hepatitis B Virus
10.1128/jvi.80.6.2797-2807.2006
O.055 The human liver-uPA-SCID mouse: a chimeric rodent model for the study of viral hepatitis
10.1016/s1386-6532(06)80061-2
A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice
10.1016/s0006-291x(03)01388-3
Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity
10.1128/jvi.02356-06
PREVENTION OF HEPATITIS B INFECTIONS : VACCINATION AND ITS LIMITATIONS
10.1179/acb.2001.032
101 HUMAN MONOCLONAL ANTIBODIES TARGETING SR-BI PREVENT HCV ENTRY AND VIRAL SPREAD IN VIVO
10.1016/s0168-8278(11)60103-7
827 EXPERIMENTAL HCV VACCINE COMBINING ADENOVIRUS AND PROTEIN ELICITS POTENT T-CELL RESPONSES AND NEUTRALIZING ANTIBODIES IN RODENTS
10.1016/s0168-8278(12)60839-3
861 THE LECTIN GRIFFITHSIN HAS ANTIVIRAL ACTIVITY AGAINST HEPATITIS C VIRUS IN VITRO AND IN VIVO
10.1016/s0168-8278(12)60873-3
Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization
10.1128/jvi.01594-10
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/aac.00633-11
In Vivo Inhibition of Anti-Hepatitis B Virus Core Antigen (HBcAg) Immunoglobulin G Production by HBcAg-Specific CD4+ Th1-Type T-Cell Clones in a hu-PBL-NOD/SCID Mouse Model
10.1128/jvi.75.23.11449-11456.2001
O.053 The human liver uPA-SCID mouse, a preclinical model to test anti-hepatitis C compounds
10.1016/s1386-6532(06)80060-0
Role of the Hepatitis C Virus Core+1 Open Reading Frame and Core cis-Acting RNA Elements in Viral RNA Translation and Replication
10.1128/jvi.01640-08
Development and Application of Hepatitis C Reporter Viruses with Genotype 1 to 7 Core-Nonstructural Protein 2 (NS2) Expressing Fluorescent Proteins or Luciferase in Modified JFH1 NS5A
10.1128/jvi.00049-11
Combined Adenovirus Vector and Hepatitis C Virus Envelope Protein Prime-Boost Regimen Elicits T Cell and Neutralizing Antibody Immune Responses
10.1128/jvi.03574-13
Animal Models to Study Hepatitis C Virus Infection.
10.3389/fimmu.2018.01032
Absence of zoonotic hepatitis E virus infection in Flemish dairy cows.
10.1016/j.ijfoodmicro.2018.05.009
Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine.
10.1038/s41598-018-24762-9
Elucidating the differences in pathogenicity between hepatitis E virus genotypes: The quest continues.
10.1002/hep4.1152
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.
10.1016/j.virol.2017.10.019
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.
10.1016/j.antiviral.2017.10.015
Murine Tissues of Human Liver Chimeric Mice Are Not Susceptible to Hepatitis E Virus Genotypes 1 and 3.
10.1093/infdis/jix422
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein.
10.1053/j.gastro.2017.09.020
Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma.
10.1016/j.antiviral.2017.02.011
Tracking HCV protease population diversity during transmission and susceptibility of founder populations to antiviral therapy.
10.1016/j.antiviral.2017.01.001
Successful Engraftment of Human Hepatocytes in uPA-SCID and FRG® KO Mice.
10.1007/978-1-4939-6506-9_8
Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.
10.1038/nmicrobiol.2016.247
Expanding the Host Range of Hepatitis C Virus through Viral Adaptation.
10.1128/mbio.01915-16
Hepatitis E virus in acute liver failure: An unusual suspect?
10.1002/hep.28759
Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
10.1128/jvi.00404-16
Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance.
10.3390/v8060176
Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line.
10.1099/jgv.0.000493
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver.
10.1136/gutjnl-2015-311109
Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge.
10.1002/hep.28428
In vitro and in vivo metabolism studies of dimethazine.
10.1002/bmc.3668
Metabolic studies of prostanozol with the uPA-SCID chimeric mouse model and human liver microsomes.
10.1016/j.steroids.2016.01.005
HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice.
10.1136/gutjnl-2015-310300
Apolipoprotein E Mediates Evasion From Hepatitis C Virus Neutralizing Antibodies.
10.1053/j.gastro.2015.09.014
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
10.1136/gutjnl-2014-309045
Host cell mTORC1 is required for HCV RNA replication.
10.1136/gutjnl-2014-308971
Assessment of Parasite Liver-Stage Burden in Human-Liver Chimeric Mice.
10.1007/978-1-4939-2815-6_5
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization.
10.3748/wjg.v20.i43.15975
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells.
10.1136/gutjnl-2012-304299
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice
10.1016/j.jhep.2012.02.018
The Green Tea Polyphenol, Epigallocatechin-3-Gallate, Inhibits Hepatitis C Virus Entry
10.1002/hep.24610
In Vivo Evaluation of the Cross-Genotype Neutralizing Activity of Polyclonal Antibodies Against Hepatitis C Virus
10.1002/hep.24171
Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice
10.1016/j.jhep.2010.03.024
Steroid metabolism in chimeric mice with humanized liver
10.1002/dta.67
The uPA(+/+)-SCID Mouse with Humanized Liver as a Model for in Vivo Metabolism of 4-Androstene-3,17-dione
10.1124/dmd.109.028183
Anti-CD81 Antibodies Can Prevent a Hepatitis C Virus Infection In Vivo
10.1002/hep.22547
Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain
10.1002/hep.22244
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
10.1073/pnas.0511218103
Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera
10.1002/hep.20657
Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry.
10.1016/j.antiviral.2017.09.006
The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
10.1016/j.antiviral.2018.07.010
Methylene Blue Treatment of Grafts During Cold Ischemia Time Reduces the Risk of Hepatitis C Virus Transmission.
10.1093/infdis/jiy386
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain.
10.1128/jvi.00939-18
Erratum: Tuning a cellular lipid kinase activity adapts hepatitis C virus to replication in cell culture.
10.1038/nmicrobiol.2017.12
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
10.1016/j.jhep.2019.01.033
Animal Models for Hepatitis E virus.
10.3390/v11060564
Hepatitis E virus prevalence in Flemish blood donors.
10.1111/jvh.13161
Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis.
10.1093/infdis/jiz171
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle.
10.1038/s41598-019-42737-2
Infectivity and stability of hepatitis C virus in different perfusion solutions.
10.1111/tid.13135
Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections.
10.1093/infdis/jiaa036
Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes.
10.1073/pnas.1919035117
Robust hepatitis E virus infection and transcriptional response in human hepatocytes.
10.1073/pnas.1912307117
Updates in Hepatitis E virus (HEV) field; lessons learned from human liver chimeric mice.
10.1002/rmv.2086
Thermostability of seven hepatitis C virus genotypes in vitro and in vivo
10.1111/jvh.12055
A Human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo
10.1002/hep.24692
STAT transcriptional activity is controlled by regulated deacetylation
10.1016/j.cyto.2012.06.223
The Sin3a repressor complex is a master regulator of STAT transcriptional activity
10.1073/pnas.1206458109
Discovery of (7R)-14-Cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic Acid (MK-3281), a Potent and Orally Bioavailable Finger-Loop Inhibitor of the Hepatitis C Virus NS5B Polymerase
10.1021/jm1013105
Lipoprotein Lipase Inhibits Hepatitis C Virus (HCV) Infection by Blocking Virus Cell Entry
10.1371/journal.pone.0026637
Metabolic studies with promagnon, methylclostebol and methasterone in the uPA(+/+)-SCID chimeric mice
10.1016/j.jsbmb.2011.06.010
Challenge Pools of Hepatitis C Virus Genotypes 1-6 Prototype Strains: Replication Fitness and Pathogenicity in Chimpanzees and Human Liver-Chimeric Mouse Models
10.1086/651579
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation
10.1084/jem.20090766
Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism
10.1002/dta.56
Detection and Characterization of a New Metabolite of 17 alpha-Methyltestosterone
10.1124/dmd.109.028373
Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry
10.1016/j.steroids.2009.05.004
HCV Animal Models: A Journey of More than 30 Years
10.3390/v1020222
Production of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing Mutations
10.1371/journal.ppat.1000475
uPA(+/+)-SCID Mouse with Humanized Liver as a Model for In Vivo Metabolism of Exogenous Steroids: Methandienone as a Case Study
10.1373/clinchem.2008.119396
Development and validation of a quantitative gas chromatography-mass spectrometry method for the detection of endogenous androgens in mouse urine
10.1016/j.chroma.2007.11.077
The human liver-uPA-SCID mouse: A model for the evaluation of antiviral compounds against HBV and HCV
10.1016/j.antiviral.2008.07.006
Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse
10.1053/j.gastro.2007.07.007
Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection
10.1016/j.cca.2005.09.022
The interferon gamma secretion assay: a reliable tool to study interferon gamma production at the single cell level
10.1016/j.jim.2004.01.001
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton.
10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling.
10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone.
10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection.
10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays.
10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection.
10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis.
10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening.
10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces.
10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR.
10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce.
10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens.
10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water.
10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries.
10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment.
10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.
10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system.
10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis.
10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids.
10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis.
10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages.
10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles.
10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis.
10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs.
10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis.
10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections.
10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420.
10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy?
10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism.
10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria.
10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization.
10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro.
10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin].
10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters.
10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action.
10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro.
10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system.
10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo.
10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges].
10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays.
10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1.
10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis.
10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways.
10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches.
10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.
10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence.
10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis.
10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings.
10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis.
10.1371/journal.pone.0026675
High-content screening in infectious diseases.
10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors.
10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease.
10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling.
10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery.
10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ.
10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.
10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems.
10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting.
10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays.
10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure.
10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP.
10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity.
10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans].
10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis.
10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva.
10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues.
10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence.
10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.
10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence.
10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine.
10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity.
10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics.
10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system.
10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.
10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors?
10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens.
10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6.
10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex.
10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family.
10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.
10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti.
10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant.
10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides.
10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection
10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology
10.1101/2021.06.30.450483
Jean Dubuisson
Dubuisson Jean
ORCID: 0000-0003-1626-7693
Addressing the next challenges: A summary of the 22nd international symposium on hepatitis C virus and related viruses
10.1016/j.jhep.2015.12.021
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents
10.1371/journal.pone.0149064
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Identification of class II ADP-ribosylation factors as cellular factors required for hepatitis C virus replication
10.1111/cmi.12572
Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin
10.1016/j.antiviral.2016.07.011
Morphology and Molecular Composition of Purified Bovine Viral Diarrhea Virus Envelope
10.1371/journal.ppat.1005476
Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver
10.1136/gutjnl-2015-311109
Alphacoronaviruses Detected in French Bats Are Phylogeographically Linked to Coronaviruses of European Bats
10.3390/v7122937
Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry
10.1039/c4nr03875d
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
10.1128/JVI.03647-14
Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro
10.1371/journal.pone.0142539
HCV envelope glycoproteins in virion assembly and entry
10.2217/FVL.14.114
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
10.1128/JVI.00991-15
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A
10.1128/JVI.00192-15
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action
10.1128/JVI.01473-15
Regulation of core expression during the hepatitis C virus life cycle
10.1099/vir.0.070433-0
A chimeric protein encompassing hepatitis C virus epitopes is able to elicit both humoral and cell-mediated immune responses in mice
10.1002/bab.1223
Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution
10.1128/JVI.01745-13
HCV-specific immune responses induced by CIGB-230 in combination with IFN-alpha plus ribavirin
10.3748/wjg.v20.i1.148
Hepatitis C Virus Capsid Protein and Intracellular Lipids Interplay and Its Association With Hepatic Steatosis
10.5812/hepatmon.17812
Hepatitis C virus life cycle and lipid metabolism
10.3390/biology3040892
Identification of a Novel Drug Lead That Inhibits HCV Infection and Cell-to-Cell Transmission by Targeting the HCV E2 Glycoprotein
10.1371/journal.pone.0111333
Identification of Conserved Residues in Hepatitis C Virus Envelope Glycoprotein E2 That Modulate Virus Dependence on CD81 and SRB1 Entry Factors
10.1128/JVI.01402-14
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
10.3390/v6031149
Neutralizing antibodies and broad, functional T cell immune response following immunization with hepatitis C virus proteins-based vaccine formulation
10.1016/j.vaccine.2014.01.046
Successful Anti-Scavenger Receptor Class B Type I (SR-BI) Monoclonal Antibody Therapy in Humanized Mice After Challenge With HCV Variants With In Vitro Resistance to SR-BI-Targeting Agents
10.1002/hep.27196
Virology and cell biology of the hepatitis C virus life cycle - An update
10.1016/j.jhep.2014.06.031
Additional Glycosylation Within a Specific Hypervariable Region of Subtype 3a of Hepatitis C Virus Protects Against Virus Neutralization
10.1093/infdis/jit376
Disulfide Bonds in Hepatitis C Virus Glycoprotein E1 Control the Assembly and Entry Functions of E2 Glycoprotein
10.1128/JVI.02659-12
EWI-2wint promotes CD81 clustering that abrogates Hepatitis C Virus entry
10.1111/cmi.12112
Hepatitis C Virus Replication and Golgi Function in Brefeldin A-Resistant Hepatoma-Derived Cells
10.1371/journal.pone.0074491
Permissivity of Primary Human Hepatocytes and Different Hepatoma Cell Lines to Cell Culture Adapted Hepatitis C Virus
10.1371/journal.pone.0070809
Phenylboronic-Acid-Modified Nanoparticles: Potential Antiviral Therapeutics
10.1021/am403770q
Structural knowledge of HCV envelope protein region recognized by broadly neutralizing antibodies
10.2217/fvl.13.75
The Antimalarial Ferroquine Is An Inhibitor of Hepatitis C Virus
10.1002/hep.26273
Virus-neutralizing antibodies to hepatitis C virus
10.1111/jvh.12094
(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry
10.1002/hep.24803
Hepatitis C Virus and Natural Compounds: A New Antiviral Approach?
10.3390/v4102197
New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets
10.1136/gutjnl-2012-302048
Role of low-density lipoprotein receptor in the hepatitis C virus life cycle
10.1002/hep.25501
Three Different Functional Microdomains in the Hepatitis C Virus Hypervariable Region 1 (HVR1) Mediate Entry and Immune Evasion
10.1074/jbc.M112.382341
Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein
10.1099/vir.0.028092-0
Comprehensive linker-scanning mutagenesis of the hepatitis C virus E1 and E2 envelope glycoproteins reveals new structure-function relationships
10.1099/vir.0.034314-0
Griffithsin Has Antiviral Activity against Hepatitis C Virus
10.1128/AAC.00633-11
HCV replication and assembly: a play in one act
10.2217/FVL.11.69
Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype
10.1128/JVI.01332-10
Hepatitis C Virus Assembly Imaging
10.3390/v3112238
Hepatitis C virus entry into the hepatocyte
10.2478/s11535-011-0076-y
Hepatocyte-derived cultured cells with unusual cytoplasmic keratin-rich spheroid bodies
10.1016/j.yexcr.2011.08.018
Identification of New Functional Regions in Hepatitis C Virus Envelope Glycoprotein E2
10.1128/JVI.02170-10
Interacting Regions of CD81 and Two of Its Partners, EWI-2 and EWI-2wint, and Their Effect on Hepatitis C Virus Infection
10.1074/jbc.M111.220103
NS2 Protein of Hepatitis C Virus Interacts with Structural and Non-Structural Proteins towards Virus Assembly
10.1371/journal.ppat.1001278
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response
10.3390/v3101909
Characterization of the Envelope Glycoproteins Associated with Infectious Hepatitis C Virus
10.1128/JVI.01180-10
Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein
10.1099/vir.0.015339-0
Identification of Basic Amino Acids at the N-Terminal End of the Core Protein That Are Crucial for Hepatitis C Virus Infectivity
10.1128/JVI.01393-10
Identification of GBF1 as a Cellular Factor Required for Hepatitis C Virus RNA Replication
10.1128/JVI.01190-09
Last Stop Before Exit - Hepatitis C Assembly and Release as Antiviral Drug Targets
10.3390/v2081782
NMR Structure and Ion Channel Activity of the p7 Protein from Hepatitis C Virus
10.1074/jbc.M110.122895
Recent Advances in Hepatitis C Virus Cell Entry
10.3390/v2030692
Role of lipid metabolism in hepatitis C virus assembly and entry
10.1042/BC20090125
Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions
10.1128/JVI.01548-10
Enhanced anti-HCV activity of interferon alpha 17 subtype
10.1186/1743-422X-6-70
Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial
10.1111/j.1365-2893.2008.01058.x
N-glycans as contributors in the biological properties of the hepatitis C virus envelope proteins
10.1684/vir.2009.0270
Occludin, the final essential factor for HCV entry?
10.2217/FVL.09.13
Rapid synchronization of hepatitis C virus infection by magnetic adsorption
10.1016/j.jviromet.2008.11.015
The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C virus entry
10.1186/1471-2180-9-111
Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry
10.1111/j.1462-5822.2007.01070.x
Early steps of the hepatitis C virus life cycle
10.1111/j.1462-5822.2007.01107.x
Hepatitis C virus (HCV)-induced immunoglobulin hypermutation reduces the affinity and neutralizing activities of antibodies against HCV envelope protein
10.1128/JVI.02582-07
Hepatitis C virus entry into host cells
10.1007/s00018-007-7291-8
Low levels of hepatitis C virus (HCV) neutralizing antibodies in patients coinfected with HCV and human immunodeficiency virus
10.1086/589777
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent
10.1128/JVI.01443-07
The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry
10.1371/journal.pone.0001866
CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection
10.1128/JVI.01573-06
Hepatitis C virus proteins
10.3748/wjg.v13.i17.2406
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus
10.1073/pnas.0705522104
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu
10.1186/1742-4690-4-8
Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors
10.1099/vir.0.82465-0
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins
10.1099/vir.0.82872-0
The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes
10.1007/s00232-007-9003-6
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein
10.1128/JVI.00127-07
Transmembrane domains of hepatitis C virus envelope glycoproteins: Residues involved in E1E2 heterodimerization and involvement of these domains in virus entry
10.1128/JVI.02198-06
Antiviral effect of alpha-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles
10.1099/vir.0.81503-0
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans
10.1074/jbc.M602431200
Hepatitis C virus entry depends on clathrin-mediated endocytosis
10.1128/JVI.00024-06
Hepatitis C virus entry: potential receptors and their biological functions
10.1099/vir.0.81646-0
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI
10.1074/jbc.M602706200
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry
10.1099/vir.0.81932-0
Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system
10.1002/hep.21406
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus
10.1128/JVI.80.6.2832-2841.2006
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2
10.1128/JVI.79.21.13199-13208.2005
Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets
10.1099/vir.0.81169-0
Basic residues in hyervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry
10.1128/JVI.79.24.15331-15341.2005
Bovine viral diarrhea virus entry is dependent on clathrin-mediated endocytosis
10.1128/JVI.79.16.10826-10829.2005
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus
10.1002/hep.20542
Contribution of the charged residues of hepatitis C virus glycoprotein E2 transmembrane domain to the functions of the E1E2 heterodimer
10.1099/vir.0.81140-0
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I
10.1074/jbc.M411600200
Interactions between virus proteins and host cell membranes during the viral life cycle
10.1016/S0074-7696(05)45006-8
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins
10.1128/JVI.79.13.8400-8409.2005
Characterization of functional hepatitis C virus envelope glycoproteins
10.1128/JVI.78.6.2994-3002.2004
Functional hepatitis C virus envelope glycoproteins
10.1016/j.biolcel.2004.03.008
Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions
10.1128/JVI.78.17.9224-9232.2004
Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein
10.4049/jimmunol.173.1.446
Positive effect of the hepatitis C virus nonstructural 5A protein on viral multiplication
10.1007/s00705-003-0291-6
Regulation of hepatitis C virus polyprotein processing by signal peptidase involves structural determinants at the p7 sequence junctions
10.1074/jbc.M406315200
Structural biology of hepatitis C virus
10.1002/hep.20032
The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals
10.1128/JVI.78.22.12591-12602.2004
Another putative receptor for hepatitis C virus
10.1002/hep.510370327
CD81-dependent binding of hepatitis C virus E1E2 heterodimers
10.1128/JVI.77.19.10677-10683.2003
Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor
10.1074/jbc.M305289200
Characterization of the expression of the hepatitis C virus F protein
10.1099/vir.0.19065-0
Glycosylation of hepatitis C virus envelope proteins
10.1016/S0300-9084(03)00004-X
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes
10.1084/jem.20021756
Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope
10.1128/JVI.77.2.813-820.2003
Topology of hepatitis C virus envelope glycoproteins
10.1002/rmv.391
Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines
10.1128/JVI.76.3.1181-1193.2002
Glycosylation of the hepatitis C virus envelope protein E1 occurs posttranslationally in a mannosylphosphoryldolichol-deficient CHO mutant cell line
10.1093/glycob/12.2.95
Interaction of hepatitis C virus proteins with host cell membranes and lipids
10.1016/S0962-8924(02)02383-8
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines
10.1006/viro.2001.1212
Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment
10.1074/jbc.M111020200
Subcellular localization and topology of the p7 polypeptide of hepatitis C virus
10.1128/JVI.76.8.3720-3730.2002
Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins
10.1093/emboj/cdf295
Biogenesis of hepatitis C virus envelope glycoproteins
10.1099/0022-1317-82-11-2589
Coexpression of hepatitis C virus envelope proteins E1 and E2 in cis improves the stability of membrane insertion of E2
10.1099/0022-1317-82-7-1629
Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization
10.1053/jhep.2001.22175
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients
10.1128/JVI.75.17.8240-8250.2001
Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins
10.1128/JVI.74.8.3623-3633.2000
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding
10.1099/0022-1317-81-12-2873
Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
10.1128/JVI.74.2.702-709.2000
Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein
10.1074/jbc.M004326200
Reciprocal relationship between alpha 1,2 mannosidase processing and reglucosylation in the rough endoplasmic reticulum of Man-P-Dol deficient cells
10.1046/j.1432-1327.2000.01111.x
The transmembrane domains of hepatitis C virus envelope glycoproteins E1 and E2 play a major role in heterodimerization
10.1074/jbc.M003003200
Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex
10.1099/0022-1317-80-4-887
Characterization of aggregates of hepatitis C virus glycoproteins
10.1099/0022-1317-80-12-3099
Retention and degradation of N-glycoproteins in the rough endoplasmic reticulum
10.1023/A:1020228725997
Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
10.1006/viro.1998.9202
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval
10.1074/jbc.273.48.32088
Characterization of truncated forms of hepatitis C virus glycoproteins
10.1099/0022-1317-78-9-2299
SYNTHESIS AND PROCESSING OF BOVINE HERPESVIRUS-1 GLYCOPROTEIN-H
10.1016/S0042-6822(95)80083-2
ATTACHMENT OF THE GAMMAHERPESVIRUS BOVINE HERPESVIRUS-4 IS MEDIATED BY THE INTERACTION OF GP8 GLYCOPROTEIN WITH HEPARIN-LIKE MOIETIES ON THE CELL-SURFACE
10.1006/viro.1993.1471
IDENTIFICATION OF 108-K, 93-K, AND 42-K GLYCOPROTEINS OF BOVINE HERPESVIRUS-1 BY MONOCLONAL-ANTIBODIES
10.1007/BF01309747
EPIDEMIOLOGIC EVALUATION OF A MONOCLONAL ELISA DETECTING BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGENS IN FIELD BLOOD-SAMPLES OF PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(92)90010-B
IDENTIFICATION AND CHARACTERIZATION OF GLYCOPROTEIN-GP1 OF BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-73-5-1293
MECHANISMS OF BOVINE HERPESVIRUS TYPE-1 NEUTRALIZATION BY MONOCLONAL-ANTIBODIES TO GLYCOPROTEIN-GI, GLYCOPROTEIN-GIII AND GLYCOPROTEIN-GIV
10.1099/0022-1317-73-8-2031
MOLECULAR-BIOLOGY OF BOVINE HERPESVIRUS TYPE-4
10.1016/0378-1135(92)90037-T
PROTEINS OF BOVINE HERPESVIRUS TYPE-4 RELEASED INTO THE CULTURE-MEDIUM OF PRODUCTIVELY INFECTED-CELLS - IDENTIFICATION OF A 135K GLYCOPROTEIN INVOLVED IN VIRAL ATTACHMENT
10.1099/0022-1317-73-1-189
A MONOCLONAL ELISA FOR BOVINE VIRAL DIARRHEA PESTIVIRUS ANTIGEN-DETECTION IN PERSISTENTLY INFECTED CATTLE
10.1016/0166-0934(91)90133-K
ANTIGENIC AND GENOMIC IDENTITY BETWEEN SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-3-715
BOVINE HERPESVIRUS-4 ISOLATES - A COMPARISON OF 3 MAJOR GLYCOPROTEINS
10.1016/0378-1135(91)90132-Y
CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVINE VIRAL DIARRHEA VIRUS - EVIDENCE OF A NEUTRALIZING ACTIVITY AGAINST GP48 IN THE PRESENCE OF GOAT ANTI-MOUSE IMMUNOGLOBULIN SERUM
10.1099/0022-1317-72-5-1195
COMPARISON OF PROTEINS OF SIMIAN HERPESVIRUS AOTUS TYPE-2 AND BOVINE HERPESVIRUS TYPE-4
10.1099/0022-1317-72-5-1145
FAILURE TO INFECT CATS WITH BOVINE HERPESVIRUS TYPE-4 STRAIN MOVAR 33/63
10.1136/vr.128.26.614
GENOMIC DIVERSITY AMONG BOVINE HERPESVIRUS-4 FIELD ISOLATES
10.1007/BF01319227
TEMPORAL CONTROL OF BOVINE HERPESVIRUS TYPE-4 GLYCOPROTEIN-SYNTHESIS
10.1099/0022-1317-72-6-1429
Bovine herpesvirus 4 genome: cloning, mapping and strain variation analysis
10.1099/0022-1317-71-1-133
Neutralization of bovine herpesvirus type 4 by pairs of monoclonal antibodies raised against two glycoproteins and identification of antigenic determinants involved in neutralization
10.1099/0022-1317-71-3-647
EXPERIMENTAL-INFECTION OF BULLS WITH A GENITAL ISOLATE OF BOVINE HERPESVIRUS-4 AND REACTIVATION OF LATENT VIRUS WITH DEXAMETHASONE
10.1016/0378-1135(89)90022-9
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL-ANTIBODIES TO BOVID HERPESVIRUS-4
10.1016/0378-1135(89)90096-5
PROTEINS SPECIFIED BY BOVINE HERPESVIRUS TYPE-4 - STRUCTURAL PROTEINS OF THE VIRION AND IDENTIFICATION OF 2 MAJOR GLYCOPROTEINS BY USING MONOCLONAL-ANTIBODIES
10.1099/0022-1317-70-7-1743
BIOLOGICAL AND BIOCHEMICAL-COMPARISON OF BOVID HERPESVIRUS-4 STRAINS
10.1016/0378-1135(88)90015-6
Identification of Novel Functions for Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly
10.1128/JVI.00048-17
Lettuce-produced hepatitis C virus E1E2 heterodimer triggers immune responses in mice and antibody production after oral vaccination
10.1111/pbi.12743
Interplay between hepatitis C virus and lipid metabolism during virus entry and assembly
10.1016/j.biochi.2017.06.009
Novel replicons and trans-encapsidation systems for Hepatitis C Virus proteins live imaging and virus-host interaction proteomics
10.1016/j.jviromet.2017.04.009
Entry and Release of Hepatitis C Virus in Polarized Human Hepatocytes
10.1128/JVI.00478-17
Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus
10.1111/jvh.12767
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
10.1016/j.virol.2017.10.019
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein
10.1053/j.gastro.2017.09.020
Identification of GBF1 as a cellular factor required for hepatitis E virus RNA replication
10.1111/cmi.12804
Secretion of Hepatitis C Virus Replication Intermediates Reduces Activation of Toll Like Receptor 3 in Hepatocytes
10.1053/j.gastro.2018.03.020
Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial)
10.1007/s40271-017-0232-1
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study
10.1371/journal.pone.0145105
The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients
10.1111/jvh.12433
Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain
10.1128/JVI.00939-18
HCoV-229E spike protein fusion activation by trypsin-like serine proteases is mediated by proteolytic processing in the S2 ' region
10.1099/jgv.0.001074
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry
10.1128/jvi.01982-17
Investigation of the role of GBF1 in the replication of positive-sense single-stranded RNA viruses
10.1099/jgv.0.001099
Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
10.3389/fimmu.2018.00910
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus Is a New Inhibitor of Hepatitis C Virus Replication
10.1101/469361
Functional and Physical Interaction between the Arf Activator GBF1 and Hepatitis C Virus NS3 Protein
10.1128/JVI.01459-18
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus , Is a New Inhibitor of Hepatitis C Virus RNA Replication
10.1128/JVI.02009-18
Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir
10.1016/j.antiviral.2019.05.002
New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle
10.1038/s41598-019-42737-2
Le virus de l’hépatite E
10.1051/medsci/2018299
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture
10.1371/journal.pone.0198226
Function of the HCV E1 envelope glycoprotein in viral entry and assembly
10.2217/fvl-2018-0180
Similarities and Differences Between HCV Pseudoparticle (HCVpp) and Cell Culture HCV (HCVcc) in the Study of HCV
10.1007/978-1-4939-8976-8_2
Use of whole-genome sequencing in the molecular investigation of care-associated HCoV-OC43 infections in a hematopoietic stem cell transplant unit
10.1016/j.jcv.2019.104206
A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice
10.1186/s12879-019-4571-5
Hepatitis C Virus Improves Human Tregs Suppressive Function and Promotes Their Recruitment to the Liver
10.3390/cells8101296
Functional Carbon Quantum Dots as Medical Countermeasures to Human Coronavirus
10.1021/acsami.9b15032
The C-terminal domain of the MERS coronavirus M protein contains a trans-Golgi network localization signal
10.1074/jbc.ra119.008964
Role of the cytosolic domain of occludin in trafficking and hepatitis C virus infection
10.1111/tra.12680
Safety and Efficacy of Avaren-Fc Lectibody Targeting HCV High-Mannose Glycans in a Human Liver Chimeric Mouse Model
10.1101/2020.04.22.056754
Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers
10.1101/2020.05.12.20098236
Les coronavirus, ennemis incertains
10.1051/medsci/2020113
Viral hepatitis in the Peruvian Amazon: Ethnomedical context and phytomedical resource
10.1016/j.jep.2020.112735
Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants
10.3390/pathogens10020172
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro
10.3390/microorganisms9020339
Rapid Generation of Coronaviral Immunity Using Recombinant Peptide Modified Nanodiamonds
10.3390/pathogens10070861
Secretory Vesicles Are the Principal Means of SARS-CoV-2 Egress
10.3390/cells10082047
Ahmed Atef Mesalam
Mesalam Ahmed Atef
/ Ahmed Atef Mesalam
ORCID: 0000-0003-4605-2976
Impact of lipids and lipoproteins on hepatitis C virus infection and virus neutralization
10.3748/wjg.v20.i43.15975
Characterization of NS3 protease from an Egyptian HCV genotype 4a isolate
10.1007/s00705-009-0500-z
Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus
10.1128/JVI.00404-16
Animal models to study hepatitis C virus infection
10.3389/fimmu.2018.01032
Polyphenols inhibit hepatitis C virus entry by a new mechanism of action
10.1128/JVI.01473-15
Characterization of a hepatitis C virus-like particle vaccine produced in a human hepatocyte-derived cell line
10.1099/jgv.0.000493
Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate
10.1002/jmv.24977
Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice
10.1136/gutjnl-2014-309045
Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1
10.1016/j.virol.2017.10.019
A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo
10.1016/j.antiviral.2017.10.015
Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents
10.1002/hep.27196
Mouse systems to model hepatitis C virus treatment and associated resistance
10.3390/v8060176
Functional study of the C-Terminal part of the hepatitis C Virus E1 ectodomain
10.1128/JVI.00939-18
Induction of Oxidative Stress and Mitochondrial Dysfunction by Juglone Affects the Development of Bovine Oocytes
10.3390/ijms22010168
Hepatitis C Virus Vaccine Development: A Step Forward
10.1093/infdis/jiaa644
Nicotinamide Supplementation during the In Vitro Maturation of Oocytes Improves the Developmental Competence of Preimplantation Embryos: Potential Link to SIRT1/AKT Signaling
10.3390/cells9061550
Melatonin Abrogates the Anti-Developmental Effect of the AKT Inhibitor SH6 in Bovine Oocytes and Embryos
10.3390/ijms20122956
Melatonin Alleviates the Toxicity of High Nicotinamide Concentrations in Oocytes: Potential Interaction with Nicotinamide Methylation Signaling
10.1155/2021/5573357